Daratumumab-based regimen for cold agglutinin disease refractory to therapy directing B-cell clone.

This document discusses a case study of a patient with primary cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia. The patient did not respond to traditional B-cell directed treatments, but showed a favorable response to a daratumumab-based regimen. The authors suggest that daratumumab may be a promising treatment option for CAD, particularly in cases that are refractory or relapsed. They also note that further research, including case series and small prospective trials, is needed to investigate the efficacy of daratumumab in CAD. [Extracted from the article]